MarketPulse
R

$RLMD

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada Therapeutics to Unveil Q4 2025 Results Amid $160M Funding Boost

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.
RLMDclinical-stage biotechprivate placement
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials